Share Twitter LinkedIn Facebook Email Pascal Besman, Chief Operating Officer of PharmaMar, talks about Submitting Update of Monotherapy to ESMO | Closure of ATLANTIS Trial in Small Cell at Annual Meeting 2018
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Lurbinectedin: Enhancing Immunotherapy Efficacy in Small Cell Lung Cancer Small Cell Lung Cancer 3 Mins Read